- Home
- GRC vs PVLA Comparison
GRC vs PVLA Comparison
Compare GRC & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GRC | PVLA |
|---|---|---|
| Founded | 1933 | 2015 |
| Country | United States | United States |
| Employees | N/A | 14 |
| Industry | Fluid Controls | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.6B |
| IPO Year | 1994 | N/A |
Fundamental Metrics
Financial Performance| Metric | GRC | PVLA |
|---|---|---|
| Price | $74.89 | $116.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 15 |
| Target Price | N/A | ★ $171.87 |
| AVG Volume (30 Days) | 86.5K | ★ 175.2K |
| Earning Date | 04-23-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.04% | N/A |
| EPS Growth | ★ 32.03 | N/A |
| EPS | ★ 0.68 | N/A |
| Revenue | ★ $682,389,000.00 | N/A |
| Revenue This Year | $6.62 | N/A |
| Revenue Next Year | $4.66 | $104,350.18 |
| P/E Ratio | $110.06 | ★ N/A |
| Revenue Growth | ★ 3.44 | N/A |
| 52 Week Low | $34.96 | $20.20 |
| 52 Week High | $79.54 | $151.18 |
Technical Indicators
Market Signals| Indicator | GRC | PVLA |
|---|---|---|
| Relative Strength Index (RSI) | 55.18 | 47.46 |
| Support Level | $43.10 | $109.68 |
| Resistance Level | $79.02 | $135.23 |
| Average True Range (ATR) | 2.25 | 5.65 |
| MACD | -0.28 | 0.02 |
| Stochastic Oscillator | 62.97 | 56.86 |
Price Performance
Historical ComparisonAbout GRC Gorman-Rupp Company (The)
Gorman-Rupp Co designs, manufactures, and globally sells pumps & pump systems for use in water, wastewater, construction, dewatering, industrial, petroleum, original equipment, agriculture, fire protection, heating, ventilating & air conditioning, military, and other liquid-handling applications. It operates in one business segment, the manufacture & sale of pumps and pump systems, and generates revenue from the same. Geographically, it generates the majority of its revenue from the United States.
About PVLA Palvella Therapeutics Inc.
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.